Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)

American Heart Journal

Volumn 143, Issue 5, 2002, Pages 847-853

  Lincoff, A Michael ^a   Kleiman, Neal S ^b   Kottke Marchant, Kandace ^a   Maierson, Elizabeth S ^a   Maresh, Kelly ^b   Wolski, Katherine E ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; BOLUS INJECTION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REOPERATION; THROMBOGENESIS; TREATMENT OUTCOME;

EID: 0036267581     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.122173     Document Type: Article

References (21)

1. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
2. Relation between activated clotting time during angioplasty and abrupt closure
3. Platelet glycoprotein IIb/IIIa blockade in coronary artery disease
4. "Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty
5. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty
6. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina
7. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study
8. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy
9. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
10. Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization
11. Enhanced survival with platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: One year outcomes and health care economic implications from a multicenter, randomized trial
12. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors
13. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4
14. Direct thrombin inhibitors in cardiovascular medicine
15. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
16. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
17. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
18. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
19. Thrombin specific inhibition by and slow cleavage of hirulog-1
20. Relation between abrupt vessel closure and the anticoagulant response to heparin and bivalirudin during coronary angioplasty
21. A randomized trial of a fixed high dose versus a weight-adjusted low dose of intravenous heparin during coronary angioplasty